stephen schuster: mosunetuzumab leads to durable complete remissions in non-hodgkin lymphoma
Published 4 years ago • 907 plays • Length 4:13Download video MP4
Download video MP3
Similar videos
-
4:50
mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma patients
-
1:45
mosunetuzumab in b-nhl r/r to car-t
-
9:36
mosunetuzumab induces complete remissions in poor prognosis non-hodgkin lymphoma
-
9:26
mosunetuzumab induces cr in b-nhl r/r to car-t
-
9:37
dual-targeted antibody mosunetuzumab elicits durable responses in poor-prognosis non-hodgkin lym...
-
1:26
mosunetuzumab in b-nhl r/r to car-t
-
1:20
subcutaneous mosunetuzumab in r/r b-cell lymphoma
-
5:28
blood review series – update on hodgkin lymphoma
-
7:09
mosunetuzumab: next-generation antibody for follicular lymphoma
-
1:21
bispecific mosunetuzumab shows promise in r/r follicular lymphoma and dlbcl
-
7:27
rajat bannerji: regn1979 active across non-hodgkin lymphoma subtypes
-
0:49
sunmo: mosunetuzumab polatuzumab vedotin vs r-gemox in r/r aggressive nhl
-
1:32
elizabeth budde, md, evaluates the clinical study investigating mosunetuzumab from ash 2018
-
2:35
ash 2019 interview - dr stephen ansell and deborah sims - hodgkin lymphoma
-
1:01:18
update on lymphoma from the 2022 american society of hematology ash annual meeting | lrf webinars
-
5:48
do early clinical data show synergy between mosunetuzumab and polatuzumab vedotin in r/r b-cell nhl?
-
7:16
dose-escalation of mosunetuzumab with polatuzumab vedotin for r/r b-cell non-hodgkin’s lymphoma
-
6:59
will bispecific antibodies challenge car t-cell therapy in follicular lymphoma? - medpage today
-
2:57
ash 2019 interview - dr laurie sehn - update: novel therapies in lymphoma